Italian Biotech Aptadir Therapeutics Raises €40 Million in Seed Round Led by 4BIO Capital
Italian biotech Aptadir Therapeutics announced the closing of a €40 million seed round led by 4BIO Capital, with participation from a range of European investors. The funding will be used to push forward its RNA‑inhibitor platform and the lead candidate for Fragile X syndrome.